Akero Therapeutics, Inc. Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2017 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Akero Therapeutics, Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2017 to Q4 2023.
  • Akero Therapeutics, Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $177M, a 62.9% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $177M +$68.4M +62.9% Dec 31, 2023 10-K 2024-02-29
Q4 2022 $109M +$41.8M +62.6% Dec 31, 2022 10-K 2024-02-29
Q4 2021 $66.9M +$30.6M +84.5% Dec 31, 2021 10-K 2024-02-29
Q4 2020 $36.2M +$20.7M +134% Dec 31, 2020 10-K 2023-03-17
Q4 2019 $15.5M +$8.71M +128% Dec 31, 2019 10-K 2022-02-25
Q4 2018 $6.8M +$5.44M +399% Dec 31, 2018 10-K 2021-03-16
Q4 2017 $1.36M Dec 31, 2017 10-K 2020-03-16
* An asterisk sign (*) next to the value indicates that the value is likely invalid.